Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate

11:24
 
공유
 

Manage episode 332745695 series 1250291
Player FM과 저희 커뮤니티의 NEJM Group 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.

Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease.

However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored the use of a monoclonal antibody–drug conjugate (trastuzumab–deruxtecan) in patients with disease they classify as HER2-“low.” Compared with “low” patients treated with one of several standard-of-care regimens, those receiving the conjugate therapy had greater median progression-free survival (roughly 10 months versus 5) and a longer overall survival (roughly 24 versus 18 months).

Christine Sadlowski of the NEJM Group interviewed Dr. Modi during the Group’s coverage of this year’s ASCO meeting, where Modi presented her results.

Have a listen.

Modi et al. as published in the New England Journal of Medicine.

The post Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate first appeared on Clinical Conversations.

128 에피소드